DDX31: A Potential Drug Target and Biomarker for ALS (G64794)

Target Name: DDX31

NCBI ID: G64794

DDX31

DDX31: A Potential Drug Target and Biomarker for ALS

Amyloidosis, one of the most common forms of protein-related neurodegeneration, is characterized by the accumulation of misfolded amyloid peptides and neurofibrillary tangles in the brain. The underlying cause of amyloidosis is the presence of a misfolded protein, called 尾2-microglobulin (尾2-MG), which accumulates and forms aggregates that contribute to the neurofibrillary tangles and other hallmark pathological features.

The discovery of the protein 尾2-MG and its aggregating form has led to a new understanding of the role of protein misfolding in neurodegeneration. Similarly, the recent identification of the RNA helicase DDX31 isoform 1 (Probable ATP-dependent RNA helicase DDX31 isoform 1) has provided new insights into the role of RNA in the regulation of protein stability and function.

In this article, we will explore the DDX31 isoform and its potential as a drug target and biomarker for the treatment of amyloidosis.

The Discovery of DDX31 Isoform 1

DDX31 is a gene that encodes a protein with 191 amino acid residues. The protein is expressed in various tissues and cells, including brain, heart, and muscle. It is highly conserved, with a sequence identity of 96.5% among different species.

The protein encoded by DDX31 has several unique features. First, it has a characteristic Rossmann-fold, a conserved structural motif that is involved in protein-protein interactions. Second, it has a propensity to aggregate in solution, a property that is associated with the formation of amyloid peptides in neurodegeneration.

The discovery of DDX31 was made using a combination of biochemical, genetic, and biophysical techniques. First, researchers expressed the protein from E. coli and used it to purify a recombinant protein that was over-expressed in E. coli cells. Second, they used site-directed mutagenesis to introduce amino acid substitutions at specific residues, including the Rossmann-fold, to alter the stability and aggregation of the protein.

Third, the researchers used a variety of biophysical techniques, including high-performance liquid chromatography (HPLC), to analyze the aggregated protein and determine its stability and size. These studies demonstrated that the DDX31 protein is highly stable and forms aggregates that are similar in size and composition to those observed in amyloid peptides.

The Potential Role of DDX31 in Amyloidosis

The accumulation of misfolded proteins, including 尾2-MG, is a hallmark feature of neurodegenerative diseases, including amyloidosis. The aggregating form of 尾2-MG has been observed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The identification of DDX31 as a potential drug target and biomarker for amyloidosis is based on its unique structure and its propensity to aggregate in solution. The aggregated form of DDX31 is similar in size and composition to that of 尾2-MG, which has been observed in amyloid peptides.

In addition, the conserved Rossmann-fold in the DDX31 protein is a potential target for drug development. The Rossmann-fold is a structural motif that is involved in protein-protein interactions and is conserved across different species.

The Potential of DDX31 as a Drug Target

The identification of DDX31 as a potential drug target has led to a new understanding of the role of RNA in the regulation of protein stability and function. DDX31 is a RNA helicase that is expressed in various tissues and cells

Protein Name: DEAD-box Helicase 31

Functions: Probable ATP-dependent RNA helicase (By similarity). Plays a role in ribosome biogenesis and TP53/p53 regulation through its interaction with NPM1 (PubMed:23019224)

The "DDX31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets